Journal: Neurobiology of Stress
Article Title: Estrogen receptor beta in the central amygdala regulates the deleterious behavioral and neuronal consequences of repeated social stress in female rats
doi: 10.1016/j.ynstr.2023.100531
Figure Lengend Snippet: Experimental Timelines. Two separate experiments were completed to determine the role of CeA ERβ signaling in the development of hypervigilant behavioral responses to repeated social stress in females. A) Rats in Experiment #1 were first assessed in a marble burying test (MB) to establish baseline levels of anxiety-like behavior, then were exposed to five consecutive days of WS or CON (15 min/day). Sessions were recorded and behaviors were assessed on days #1 (D1) and #5 (D5). WS/CON rats underwent a post-WS/CON MB test to determine how exposure to repeated WS affects measures of hypervigilant and anxiety-like behaviors. Six days after the final WS/CON exposure, rats were re-exposed to the context in which they originally experienced either WS (but in the absence of the resident) or CON for 15 min. Brains were collected 30 min after the start of WS/CON context exposure. B) For Experiment #2, all rats were implanted with indwelling bilateral cannulas into the CeA. Following surgical recovery, a pre-stress testing regimen commenced to assess baseline sucrose preference (SPT) and acoustic startle response (ASR). Subsequently, rats were exposed to five consecutive days of WS/CON (15 min/day) with local microinjection of either vehicle or the ERβ antagonist, PHTPP, into the CeA 1 h prior to each WS/CON session. Post-WS/CON behavioral testing consisted of the elevated plus maze (EPM), SPT, ASR, and MB, each separated by 24 h, to determine if ERβ blockade, through PHTPP, prevented the development of hypervigilant, anxiety-like, and reward motivated behaviors. Tissue was collected at rest two days following the final behavioral test. CeA: Central Amygdala; ERβ: estrogen receptor beta.
Article Snippet: One hour prior to each WS/CON exposure, females in Experiment #2 received either vehicle (10% dimethyl sulfoxide [DMSO], Fisher Scientific, Pittsburgh, PA) in saline, or the potent and selective ERβ antagonist, 4-[2-Phenyl-5,7- bis (trifluoromethyl)pyrazolol[1,5- a ]pyrimidin-3-yl]phenol (PHTPP, 10 μM dissolved in 10% DMSO, TOCRIS, Minneapolis, MN), microinjected bilaterally into the CeA (0.5 μL over 1 min with a 1-min wait post-infusion) ( ).
Techniques: Microinjection